GeneDx: The 50% Crash Creates A Compelling Entry

GeneDX (WGS) experienced a 50% stock drop after Q1 misses and FY26 guidance cut, yet volume grew 34% YoY, outpacing internal forecasts. Revenue shortfall was due to mix shift toward lower-ARR genome tests and non-core weakness, not demand or pricing issues. Genome adoption is accelerating, supporting a bullish thesis as payer coverage expands, automation improves, and new channels like general pediatrics ramp.